Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Feb;9(2):e01215.
doi: 10.1002/brb3.1215. Epub 2019 Jan 18.

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis

Lin Han  1 , Yao Liu  2 , Hai Xiong  1   3 , Peiwei Hong  1
Affiliations
Meta-Analysis

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis

Lin Han et al. Brain Behav. 2019 Feb.

Abstract

Background: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta-analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic migraine.

Methods: Database including Cochrane Library and PubMed were systematically searched for randomized controlled trials (RCTs) which are about CGRP mAb in preventing treatment of chronic migraine. Evaluating the bias and quality of RCTs was carried out according to the Cochrane collaboration's tool for assessing risk of bias. The data analysis was carried out by reviewer manager 5.2.

Results: Totally, 6 articles enrolled in the present meta-analysis, including 4 independent clinical trials and 3,166 patients. After pooled analysis, it indicated that CGRP mAb improved 50% responder rate (OR = 2.42, 95% CI = [2.04, 2.87], I2 = 0%, p < 0.00001) and 75% responder rate (OR = 1.95, 95% CI = [1.30, 2.91], I2 = 0%, p = 0.001), as compared with placebo. And there was no difference in incidence of adverse events between CGRP mAb group and placebo group except incidence of injection site discomfort.

Conclusions: CGRP mAb is an effective and safety preventive treatment for chronic migraine.

Keywords: CGRP; calcitonin gene-related peptide; chronic migraine; meta-analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart
Figure 2
Figure 2
Responder rate
Figure 3
Figure 3
Secondary efficacy outcomes
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bigal, M. E. , Edvinsson, L. , Rapoport, A. M. , Lipton, R. B. , Spierings, E. L. H. , Diener, H.‐C. , … Silberstein, S. D. (2015). Safety, tolerability, and efficacy of TEV‐48125 for preventive treatment of chronic migraine: A multicentre, randomised, double‐blind, placebo‐controlled, phase 2b study. The Lancet Neurology, 14(11), 1091–1100. 10.1016/S1474-4422(15)00245-8 - DOI - PubMed
    1. Deen, M. , Correnti, E. , Kamm, K. , Kelderman, T. , Papetti, L. , Rubio‐Beltrán, E. , … Maassen Van Den Brink, A. (2017). Blocking CGRP in migraine patients ‐ a review of pros and cons. The Journal of Headache and Pain, 18(1), 96 10.1186/s10194-017-0807-1 - DOI - PMC - PubMed
    1. Deneris, A. , Rosati Allen, P. , Hart Hayes, E. , & Latendresse, G. (2017). Migraines in women: Current evidence for management of episodic and chronic migraines. Journal of Midwifery & Women's Health, 62(3), 270–285. 10.1111/jmwh.12626 - DOI - PubMed
    1. Detke, H. C. , Goadsby, P. J. , Wang, S. , Friedman, D. I. , Selzler, K. J. , & Aurora, S. K. (2018). Galcanezumab in chronic migraine: The randomized, double‐blind, placebo‐controlled REGAIN study. Neurology, 91(24), e2211–e2221. 10.1212/WNL.0000000000006640 - DOI - PMC - PubMed
    1. Giacomozzi, A. R. , Vindas, A. P. , Silva, A. A. Jr , Bordini, C. A. , Buonanotte, C. F. , Roesler, C. A. , … Filho, P. F. (2013). Latin American consensus on guidelines for chronic migraine treatment. Arquivos De Neuro‐Psiquiatria, 71(7), 478–486. 10.1590/0004-282X20130066 - DOI - PubMed

Publication types

MeSH terms

Substances